Pacira (PCRX) BioSciences announced new data from its ongoing Phase 1 study of its gene therapy candidate PCRX-201. The data is being presented at the 2025 European Alliance of Associations for Rheumatology, EULAR, Annual Congress, taking place from June 11-14, in Barcelona, Spain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PCRX: